drugset / Trial / NCT04714229
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
RandomizedParallel-groupTriple-blindPrevention
Summary
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, and Y)-CRM197 Conjugate vaccine
Timeline
- Start
- 2020-09-01
- Primary completion
- 2020-11-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine | Vaccine | 0.5 ml | Intramuscular |